Working… Menu

Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002689
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : July 18, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy combined with chemotherapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of brachytherapy followed by external-beam radiation therapy plus chemotherapy in treating patients who have pancreatic cancer that cannot be removed surgically.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: dexamethasone Drug: fluorouracil Radiation: brachytherapy Radiation: phosphorus P32 Radiation: radiation therapy Phase 2

Detailed Description:


  • Determine the response/remission rate, survival, and degree of local control from interstitial colloidal phosphorus P32 followed by external beam radiotherapy and chemotherapy in patients with unresectable pancreatic cancer.

OUTLINE: Patients are stratified according to prior therapy (yes vs no).

Patients receive dexamethasone intratumorally, then macroaggregated albumin and interstitial phosphorus P32 intratumorally. Most patients receive a second course of this brachytherapy.

Patients then proceed to chemoradiotherapy beginning 7-14 days after brachytherapy. Radiotherapy is administered 5 days a week for 6.4 weeks. Fluorouracil IV is administered every other day for 4 doses during weeks 1 and 2.

Patients are followed monthly for 1 year then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Primary Purpose: Treatment
Official Title: Phase II Interstitial Colloidal 32P Integrated in The Treatment of Non-Resectable Pancreatic Cancer
Study Start Date : September 1995
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Response rate
  2. Duration of remission
  3. Survival

Secondary Outcome Measures :
  1. Patterns of failure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically proven unresectable adenocarcinoma of the pancreas limited to the head, body, or tail of the pancreas

    • Diameter no greater than 5 cm
    • Volume no greater than 66 mL
  • No ascites (with or without tumor cells)
  • No endoscopically proven tumor penetration of duodenum or stomach



  • 18 and over

Performance status:

  • Karnofsky 70-100%


  • WBC at least 3,000/mm3
  • Platelet count at least 100,000/mm3
  • Hemoglobin at least 9 g/dL (transfusion allowed)


  • No hepatic disease
  • At least 50% uptake of technetium-sulfur colloid in normal liver if cirrhosis suspected
  • No vascular occlusion of portal system


  • Creatinine no greater than 1.5 mg/dL
  • BUN no greater than 25 mg/dL


  • No Crohn's disease, ulcerative colitis, or other inflammatory bowel disease
  • Not pregnant


Biologic therapy:

  • Not specified


  • If prior chemotherapy, test dose of colloidal phosphorous P32 administered prior to attempted treatment

Endocrine therapy:

  • Not specified


  • No prior radiotherapy to pancreas, liver, or upper gastrointestinal tract


  • No complete surgical resection
  • No splenectomy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00002689

Layout table for location information
United States, Georgia
Northside Hospital Cancer Center
Atlanta, Georgia, United States, 30342-1611
United States, New York
Center for Molecular Medicine
Garden City, New York, United States, 11530
Sponsors and Collaborators
Center for Molecular Medicine
Layout table for investigator information
Study Chair: Stanley E. Order, MD, ScD, FACR Center for Molecular Medicine

Layout table for additonal information Identifier: NCT00002689     History of Changes
Other Study ID Numbers: CMM-95079
CDR0000064415 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: July 18, 2013
Last Verified: June 2007
Keywords provided by National Cancer Institute (NCI):
stage I pancreatic cancer
stage II pancreatic cancer
stage III pancreatic cancer
adenocarcinoma of the pancreas
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors